AzurRx is bolstering its pipeline and assuming a new name through its acquisition of First Wave Bio. The cash-and-stock deal could be worth up to $229 million and includes future payments if ...
– Inflammatory bowel disease (IBD) represents a multi-billion dollar market opportunity with current therapies achieving a clinical remission rate of less than 20% on average Carlsbad, CA, Sept. 06, ...
Ironwood Pharmaceuticals has established itself as a leader in the gastrointestinal healthcare space with its innovative products and pipeline development. The demand for LINZESS, a therapy for ...
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 Carlsbad, CA, Sept. 06, 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results